Stay updated on Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedUpgrade to v3.2.0 with an inserted government operating status notice; previous version v3.1.0 removed.SummaryDifference4%
- Check23 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%
- Check30 days agoChange DetectedNew sponsor and study details added (Vanda Pharmaceuticals; a single-arm, multiple-dose study of imsidolimab for GPP with a detailed description and date references). The old sponsor/links from AnaptysBio, Inc. were removed.SummaryDifference5%
- Check37 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%
- Check51 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations, while also removing previous location-related terms and outdated references.SummaryDifference4%
Stay in the know with updates to Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.